SG11201804136SA - Inhibitors of cxcr2 - Google Patents
Inhibitors of cxcr2Info
- Publication number
- SG11201804136SA SG11201804136SA SG11201804136SA SG11201804136SA SG11201804136SA SG 11201804136S A SG11201804136S A SG 11201804136SA SG 11201804136S A SG11201804136S A SG 11201804136SA SG 11201804136S A SG11201804136S A SG 11201804136SA SG 11201804136S A SG11201804136S A SG 11201804136SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- drive
- avenue
- cxcr2
- pct
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000002791 Interleukin-8B Receptors Human genes 0.000 abstract 3
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 240000000731 Fagus sylvatica Species 0.000 abstract 1
- 235000010099 Fagus sylvatica Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau irst0) (43) International Publication Date .... ...../ 26 May 2017(26.05.2017) WIPO I PCT II (10) WO International 1111111111111111111111111111111111111111111111111111111 2017/087610 Publication DID Number Al IIIIRIIIIIIIIIIIIIII (51) International Patent Classification: (72) Inventors: CHEN, Xi; 1198 Beech Street, E. Palo Alto, A61K 31/407 (2006.01) A61K 31/5377 (2006.01) CA 94303 (US). DRAGOLI, Dean, R.; 24645 Summerhill A61K 31/404 (2006.01) Avenue, Los Altos, CA 94024 (US). FAN, Junfa; 4292 (21) International Application Number: Wilkie Way, #H, Palo Alto, CA 94306 (US). KALISIAK, PCT/US2016/062427 Jaroslaw; 1031 Crestview Drive, Apt. 104, Mountian View, CA (US). LELETI, Manmohan, Reddy; 7269 (22) International Filing Date: Ventana Drive, San Jose, CA 95129 (US). MALA- 17 November 2016 (17.11.2016) THONG, Viengkham; 121988 San Luis Avenue, #3, (25) Filing Language: English Mountain View, CA 94043 (US). MCMAHON, Jeffrey; 15 Alta Mar Way, San Francisco, CA 94121 (US). (26) Publication Language: English TANKAKA, Hiroko; 600 Rainbow Drive, #148, Moun- tain View, CA 94041 (US). YANG, Ju; 966 Clara Drive, (30) Priority Data: Palo Alto, CA 94303 (US). YU, Chao; 555 E. Washington 62/257,529 19 November 2015 (19.11.2015) US Avenue, Apt. 1105, Sunnyvale, CA 94086 (US) ZHANG, (71) Applicant: CHEMOCENTRYX, INC. [US/US]; 850 Penglie; 1036 Jamaica Street, Foster City, CA 94404 (US). Maude Avenue, Mountain View, CA 94043 (US). [Continued on next page] (54) Title: INHIBITORS OF CXCR2 (57) : Compounds are provided as inhibitors of CXCR2, hav- FIGURE IA ing the structure (I). CXCR2 IC 50 (nM) 0 0 c N N. N ° +++ 0 CONHz . . 1.001 / O r_ n N g r t vro &I ° 1.002 Fy + O COSH ilk 1.003 0 0 N 0 ° ++ \ / 1.004 o F O N N- ry 0 0 + co2H al 1.005 7 l ' -- ` ' ,.. ,,, Es /O wur N N +++ I'l 1.006 N 0 0 / .4t formula (I) : R ab 0 0 11 R 5 a / 71 Rsa \ = R 36 IN R fib -._ N X H H Ge R 6 a 0 R 2 0 Ril R1 IN I'l 0 ei O WO 2017/087610 Al MIDEDIMOMOIDEIRMEMONIMMOMEMMIDEVOIMIE MALI, Venkat; 20800 Valley Green Drive, #427, Cuper- tino, CA 95014 (US). SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (74) (81) Agents: KEZER, William B. et al.; Mintz Levin Cohn (84) Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, Published: MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, — NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, with international search report (Art. 21(3)) RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV,
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257529P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/062427 WO2017087610A1 (en) | 2015-11-19 | 2016-11-17 | Inhibitors of cxcr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804136SA true SG11201804136SA (en) | 2018-06-28 |
Family
ID=58717757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804136SA SG11201804136SA (en) | 2015-11-19 | 2016-11-17 | Inhibitors of cxcr2 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9809581B2 (en) |
| EP (1) | EP3377059B1 (en) |
| JP (1) | JP6901479B2 (en) |
| KR (1) | KR20180100556A (en) |
| CN (1) | CN108601766B (en) |
| AR (1) | AR106757A1 (en) |
| AU (1) | AU2016355654B2 (en) |
| BR (1) | BR112018010118B1 (en) |
| CA (1) | CA3005737C (en) |
| DK (1) | DK3377059T3 (en) |
| EA (1) | EA035417B1 (en) |
| ES (1) | ES2841912T3 (en) |
| IL (1) | IL259354B (en) |
| MX (1) | MX2018006148A (en) |
| NZ (1) | NZ742819A (en) |
| PL (1) | PL3377059T3 (en) |
| PT (1) | PT3377059T (en) |
| SG (1) | SG11201804136SA (en) |
| TW (1) | TWI724056B (en) |
| WO (1) | WO2017087610A1 (en) |
| ZA (1) | ZA201803436B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI734715B (en) * | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | Modulators of chemokine receptors |
| TWI724056B (en) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Inhibitors of cxcr2 |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288A (en) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | Compositions and methods for CAR T cell therapy |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| AU2018318075B2 (en) | 2017-08-14 | 2023-04-13 | Allergan, Inc. | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof |
| CA3087701A1 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
| BR112020014913A2 (en) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | METHODS FOR USE OF T CAR CELLS |
| PE20211070A1 (en) | 2018-09-21 | 2021-06-09 | Pfizer | DIOXOCYCLOBUTENYLAMINE-3-HYDROXY-PICOLINAMIDAS N-SUBSTITUTED USEFUL AS INHIBITORS OF CCR6 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| JP2022527835A (en) * | 2019-04-08 | 2022-06-06 | ピーアイ インダストリーズ リミテッド | A novel oxadiazole compound for controlling or preventing phytopathogenic fungi |
| US11872217B2 (en) | 2019-07-10 | 2024-01-16 | Chemocentryx, Inc. | Indanes as PD-L1 inhibitors |
| CN112274511B (en) * | 2019-07-22 | 2024-04-02 | 正大天晴药业集团股份有限公司 | Quinoline derivatives for the treatment of graft versus host disease |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN113018438B (en) * | 2019-12-24 | 2022-06-17 | 四川大学 | Application of CXCR2 inhibitor in preparation of medicine for treating nasopharyngeal carcinoma |
| US20230079843A1 (en) * | 2020-01-19 | 2023-03-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treating rheumatoid arthritis |
| CN113995839B (en) * | 2021-10-11 | 2023-03-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Application of CXCR2 inhibitor in improvement of tumor immune microenvironment |
| CN113952453B (en) * | 2021-10-11 | 2023-01-24 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Application of CXCR2 inhibitor in preparation of drugs for treating tumors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| AR033803A1 (en) | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | DIANILINO ESCUARANO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, AND THE USE OF THE SAME IN THE MANUFACTURE OF MEDICINES TO TREAT CHEMIOQUINE MEDIUM-RELATED DISEASES |
| AU2001266640A1 (en) | 2000-05-30 | 2001-12-11 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| DE60230722D1 (en) | 2001-01-16 | 2009-02-26 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| EP1351933B1 (en) | 2001-01-16 | 2006-11-22 | SmithKline Beecham Corporation | Il-8 receptor antagonists |
| US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| CZ20032098A3 (en) | 2001-02-02 | 2004-01-14 | Schering Corporation | 3,4-Disubstituted cyclobutene-1,2-diones and pharmaceutical composition containing thereof |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| DK1381590T3 (en) * | 2001-04-16 | 2007-10-22 | Schering Corp | 3,4-disubstituted cyclobutene-1,2-dione as CXC chemokine receptor ligands |
| CA2479126C (en) | 2002-03-18 | 2011-11-15 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| ES2338657T3 (en) | 2003-04-18 | 2010-05-11 | Schering Corporation | SYNTHESIS OF 2-HYDROXI-N, N-DIMETHYL-3 - ((2 - ((1 (R) - (5-METHYL-2-FURANIL) PROPIL) AMINO) -3,4-DIOXO-1-CICLOBUTEN-1 -IL) AMINO) BENZAMIDA. |
| PE20051093A1 (en) | 2004-01-30 | 2006-01-16 | Schering Corp | CRYSTALLINE POLYMORPHES OF A CXC CHEMOKINE RECEPTOR LIGAND |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| DE102005035742A1 (en) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections |
| KR20090028811A (en) * | 2006-07-07 | 2009-03-19 | 쉐링 코포레이션 | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| WO2008055570A1 (en) | 2006-11-07 | 2008-05-15 | Thyssenkrupp Drauz Nothelfer Gmbh | Method and system for producing reinforced sheet metal blanks |
| CA2680173A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| FR2915147B1 (en) | 2007-04-17 | 2010-01-15 | Peugeot Citroen Automobiles Sa | SEAT FOR CONVERTIBLE MOTOR VEHICLE IN CHILD SEAT BACK TO ROAD AND ASSOCIATED MOTOR VEHICLE. |
| KR20100031718A (en) | 2007-06-06 | 2010-03-24 | 노파르티스 아게 | Anti-inflammatory substituted cyclobutenedione compounds |
| US8519168B2 (en) | 2007-07-03 | 2013-08-27 | Merck Sharp & Dohme Corp. | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| CA2694268A1 (en) | 2007-07-05 | 2009-01-08 | Schering Corporation | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| US20100267712A1 (en) | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| MX2010006089A (en) | 2007-12-04 | 2010-09-22 | Schering Corp | Methods of treating copd. |
| EP2318369A1 (en) | 2008-06-24 | 2011-05-11 | TopoTarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| JP2012505898A (en) | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | Pyrrolidine, piperidine and piperazine derivatives and methods for their use |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) * | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
| WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (en) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| EP2760821B1 (en) | 2011-09-02 | 2017-10-11 | Novartis AG | Choline salt of an anti-inflammatory substituted cyclobutenedione compound |
| FR2981934B1 (en) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
| FR2981935B1 (en) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
| FR2981936B1 (en) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | NOVEL DI-SUBSTITUTED DIAMINO-3,4-CYCLOBUTENE-3-DIONE-1,2 COMPOUNDS USEFUL IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES. |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| WO2015170430A1 (en) | 2014-05-08 | 2015-11-12 | 学校法人慶應義塾 | Suppressant for post-aortic dissection inflammatory disorder |
| EP3220951A1 (en) | 2014-11-17 | 2017-09-27 | MedImmune Limited | Therapeutic combinations and methods for treating neoplasia |
| TWI734715B (en) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | Modulators of chemokine receptors |
| TWI724056B (en) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Inhibitors of cxcr2 |
| CA3087701A1 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
-
2016
- 2016-11-14 TW TW105136997A patent/TWI724056B/en active
- 2016-11-17 BR BR112018010118-4A patent/BR112018010118B1/en active Search and Examination
- 2016-11-17 WO PCT/US2016/062427 patent/WO2017087610A1/en active Application Filing
- 2016-11-17 EA EA201891211A patent/EA035417B1/en not_active IP Right Cessation
- 2016-11-17 CA CA3005737A patent/CA3005737C/en active Active
- 2016-11-17 DK DK16867099.0T patent/DK3377059T3/en active
- 2016-11-17 KR KR1020187017289A patent/KR20180100556A/en not_active Application Discontinuation
- 2016-11-17 PT PT168670990T patent/PT3377059T/en unknown
- 2016-11-17 EP EP16867099.0A patent/EP3377059B1/en active Active
- 2016-11-17 US US15/353,949 patent/US9809581B2/en active Active
- 2016-11-17 CN CN201680068015.9A patent/CN108601766B/en active Active
- 2016-11-17 PL PL16867099T patent/PL3377059T3/en unknown
- 2016-11-17 JP JP2018526187A patent/JP6901479B2/en active Active
- 2016-11-17 SG SG11201804136SA patent/SG11201804136SA/en unknown
- 2016-11-17 MX MX2018006148A patent/MX2018006148A/en unknown
- 2016-11-17 AU AU2016355654A patent/AU2016355654B2/en active Active
- 2016-11-17 NZ NZ742819A patent/NZ742819A/en unknown
- 2016-11-17 ES ES16867099T patent/ES2841912T3/en active Active
- 2016-11-18 AR ARP160103547A patent/AR106757A1/en unknown
-
2017
- 2017-10-02 US US15/722,785 patent/US10370363B2/en active Active
-
2018
- 2018-05-14 IL IL259354A patent/IL259354B/en active IP Right Grant
- 2018-05-24 ZA ZA2018/03436A patent/ZA201803436B/en unknown
-
2019
- 2019-06-12 US US16/438,880 patent/US11040960B2/en active Active
-
2021
- 2021-04-29 US US17/243,872 patent/US11945805B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804136SA (en) | Inhibitors of cxcr2 | |
| SG11201808625QA (en) | SOLUBLE C5aR ANTAGONISTS | |
| SG11201804133PA (en) | Modulators of chemokine receptors | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201810387YA (en) | Magnetized catheters, devices, uses and methods of using magnetized catheters | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201909383PA (en) | Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201811259YA (en) | Single payment device for multiple payment accounts | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof |